Adding ribavirin to interferon alpha-2b for chronic hepatitis C infection increased virological response and nausea.
Schalm
S W
SW
Department of Hepatogastroenterology, Erasmus University Hospital Rotterdam - Dijkzigt, PO Box 2040, 3000 CA Rotterdam, The Netherlands (email: devlaming@inw2.azr.nl).
D000998:Antiviral Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009325:Nausea / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin